{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:00:57Z","timestamp":1792098057604,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T00:00:00Z","timestamp":1326240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00417-011-1908-1","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T03:59:16Z","timestamp":1326167956000},"page":"1081-1087","source":"Crossref","is-referenced-by-count":16,"title":["Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Beh\u00e7et\u2019s disease with infliximab"],"prefix":"10.1007","volume":"250","author":[{"given":"Daiju","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Mizuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Kitaichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,11]]},"reference":[{"key":"1908_CR1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1755-3768.2008.01282.x","volume":"87","author":"H Kitamei","year":"2009","unstructured":"Kitamei H, Kitaichi N, Namba K, Kotake S, Goda C, Kitamura M, Miyazaki A, Ohno S (2009) Clinical features of intraocular inflammation in Hokkaido, Japan. Acta Ophthalmol 87:424\u2013428","journal-title":"Acta Ophthalmol"},{"key":"1908_CR2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Beh\u00e7et\u2019s disease: an international collaborative study. Br J Ophthalmol 91:1579\u20131582","journal-title":"Br J Ophthalmol"},{"key":"1908_CR3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/bjo.2008.154476","volume":"93","author":"N Kitaichi","year":"2009","unstructured":"Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S (2009) Low prevalence of juvenile-onset Beh\u00e7et\u2019s disease with uveitis in East\/South Asian people. Br J Ophthalmol 93:1428\u20131430","journal-title":"Br J Ophthalmol"},{"key":"1908_CR4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","volume":"27","author":"V Kaklamani","year":"1998","unstructured":"Kaklamani V, Vaiopoulos G, Kaklamanis P (1998) Beh\u00e7et\u2019s disease. Semin Arthritis Rheum 27:197\u2013217","journal-title":"Semin Arthritis Rheum"},{"key":"1908_CR5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G (1999) Beh\u00e7et\u2019s disease. N Engl J Med 341:1284\u20131291","journal-title":"N Engl J Med"},{"key":"1908_CR6","first-page":"488","volume":"150","author":"C Zouboulis","year":"1999","unstructured":"Zouboulis C (1999) Epidemiology of Adamantiades-Beh\u00e7et\u2019s disease. Ann Med Interne (Paris) 150:488\u2013498","journal-title":"Ann Med Interne (Paris)"},{"key":"1908_CR7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"D Knight","year":"1993","unstructured":"Knight D, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore M, Vilcek J, Daddona P (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443\u20131453","journal-title":"Mol Immunol"},{"key":"1908_CR8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","volume":"344","author":"M Elliott","year":"1994","unstructured":"Elliott M, Maini R, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody J (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125\u20131127","journal-title":"Lancet"},{"key":"1908_CR9","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"1908_CR10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, Rachmilewitz D, Wolf D, Olson A, Bao W, Rutgeerts P, Group AIS","year":"2002","unstructured":"Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, Rachmilewitz D, Wolf D, Olson A, Bao W, Rutgeerts P, Group AIS (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 359:1541\u20131549","journal-title":"Lancet"},{"key":"1908_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00063-009-1024-8","volume":"104","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Schmitt J, Wozel G, Kirch W (2009) Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin (Munich) 104:125\u2013136","journal-title":"Med Klin (Munich)"},{"key":"1908_CR12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"F Nestle","year":"2009","unstructured":"Nestle F, Kaplan D, Barker J (2009) Psoriasis. N Engl J Med 361:496\u2013509","journal-title":"N Engl J Med"},{"key":"1908_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"P Sfikakis","year":"2001","unstructured":"Sfikakis P, Theodossiadis P, Katsiari C, Kaklamanis P, Markomichelakis N (2001) Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 358:295\u2013296","journal-title":"Lancet"},{"key":"1908_CR14","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","volume":"358","author":"S Mu\u00f1oz-Fern\u00e1ndez","year":"2001","unstructured":"Mu\u00f1oz-Fern\u00e1ndez S, Hidalgo V, Fern\u00e1ndez-Mel\u00f3n J, Schlincker A, Mart\u00edn-Mola E (2001) Effect of infliximab on threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 358:1644","journal-title":"Lancet"},{"key":"1908_CR15","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol 31:1362\u20131368","journal-title":"J Rheumatol"},{"key":"1908_CR16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"P Sfikakis","year":"2004","unstructured":"Sfikakis P, Kaklamanis P, Elezoglou A, Katsilambros N, Theodossiadis P, Papaefthimiou S, Markomichelakis N (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med 140:404\u2013406","journal-title":"Ann Intern Med"},{"key":"1908_CR17","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, G\u00fcl A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"1908_CR18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia M, Paroli M, Priori R, Conti F, Pivetti-Pezzi P (2007) Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol 51:191\u2013196","journal-title":"Jpn J Ophthalmol"},{"key":"1908_CR19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassar\u00e0 E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study. Rheumatology (Oxford) 46:1161\u20131164","journal-title":"Rheumatology (Oxford)"},{"key":"1908_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"H Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M (2008) Safety and efficacy of infliximab therapy in active Beh\u00e7et\u2019s uveitis: an open-label trial. Rheumatol Int 29:53\u201357","journal-title":"Rheumatol Int"},{"key":"1908_CR21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease. Br J Ophthalmol 94:284\u2013288","journal-title":"Br J Ophthalmol"},{"key":"1908_CR22","first-page":"S65","volume":"25","author":"A Elezoglou","year":"2007","unstructured":"Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, Vaiopoulos G, Sfikakis PP (2007) Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 25:S65\u2013S69","journal-title":"Clin Exp Rheumatol"},{"key":"1908_CR23","first-page":"59","volume":"10","author":"Y Mizushima","year":"1988","unstructured":"Mizushima Y (1988) Recent research into Beh\u00e7et\u2019s disease in Japan. Int J Tissue React 10:59\u201365","journal-title":"Int J Tissue React"},{"key":"1908_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Group SoUNSW","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Group SoUNSW (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"1908_CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0090-1229(85)90045-5","volume":"36","author":"MJ Fritzler","year":"1985","unstructured":"Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ (1985) Antinuclear, anticytoplasmic, and anti-Sj\u00f6gren\u2019s syndrome antigen A (SS-A\/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 36:120\u2013128","journal-title":"Clin Immunol Immunopathol"},{"key":"1908_CR26","first-page":"393","volume":"11","author":"K Vlam de","year":"1993","unstructured":"de Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D\u2019Haese D, Veys EM (1993) Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 11:393\u2013397","journal-title":"Clin Exp Rheumatol"},{"key":"1908_CR27","first-page":"137","volume":"12","author":"J Forslid","year":"1994","unstructured":"Forslid J, Heigl Z, Jonsson J, Scheynius A (1994) The prevalence of antinuclear antibodies in healthy young persons and adults, comparing rat liver tissue sections with HEp-2 cells as antigen substrate. Clin Exp Rheumatol 12:137\u2013141","journal-title":"Clin Exp Rheumatol"},{"key":"1908_CR28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780400909","volume":"40","author":"EM Tan","year":"1997","unstructured":"Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA (1997) Range of antinuclear antibodies in \"healthy\" individuals. Arthritis Rheum 40:1601\u20131611","journal-title":"Arthritis Rheum"},{"key":"1908_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S0041-87812003000600005","volume":"58","author":"SA Fernandez","year":"2003","unstructured":"Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, AM Prigo, Rivitti EA (2003) Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo 58:315\u2013319","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"1908_CR30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.20096","volume":"50","author":"A Watanabe","year":"2004","unstructured":"Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, Tomita Y, Muro Y (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892\u2013900","journal-title":"Arthritis Rheum"},{"key":"1908_CR31","first-page":"313","volume":"25","author":"AA Al Jabri","year":"2004","unstructured":"Al Jabri AA, Al Buloshi MS (2004) Anticardiolipin and antinuclear antibodies in the adult healthy Omani individuals. Saudi Med J 25:313\u2013317","journal-title":"Saudi Med J"},{"key":"1908_CR32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"L Rycke De","year":"2003","unstructured":"De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48:1015\u20131023","journal-title":"Arthritis Rheum"},{"key":"1908_CR33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08916930400021378","volume":"38","author":"O Elkayam","year":"2005","unstructured":"Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D (2005) Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 38:155\u2013160","journal-title":"Autoimmunity"},{"key":"1908_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson C, Engstrand S, Sundqvist KG, Rantap\u00e4\u00e4-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64:403\u2013407","journal-title":"Ann Rheum Dis"},{"key":"1908_CR35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2133.2009.09563.x","volume":"162","author":"AE Pink","year":"2010","unstructured":"Pink AE, Fonia A, Allen MH, Smith CH, Barker JN (2010) Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 162:780\u2013785","journal-title":"Br J Dermatol"},{"key":"1908_CR36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","volume":"11","author":"S Nancey","year":"2005","unstructured":"Nancey S, Blanvillain E, Parmentier B, Flouri\u00e9 B, Bayet C, Bienvenu J, Fabien N (2005) Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn\u2019s disease. Inflamm Bowel Dis 11:986\u2013991","journal-title":"Inflamm Bowel Dis"},{"key":"1908_CR37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2133.2006.07316.x","volume":"155","author":"CH Smith","year":"2006","unstructured":"Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN (2006) Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155:160\u2013169","journal-title":"Br J Dermatol"},{"key":"1908_CR38","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"PJ Charles","year":"2000","unstructured":"Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383\u20132390","journal-title":"Arthritis Rheum"},{"key":"1908_CR39","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","volume":"61","author":"AP Cairns","year":"2002","unstructured":"Cairns AP, Duncan MK, Hinder AE, Taggart AJ (2002) New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61:1031\u20131032","journal-title":"Ann Rheum Dis"},{"key":"1908_CR40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"M Debandt","year":"2003","unstructured":"Debandt M, Vittecoq O, Descamps V, Le Lo\u00ebt X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22:56\u201361","journal-title":"Clin Rheumatol"},{"key":"1908_CR41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","volume":"11","author":"EG Favalli","year":"2002","unstructured":"Favalli EG, Sinigaglia L, Varenna M, Arnoldi C (2002) Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11:753\u2013755","journal-title":"Lupus"},{"key":"1908_CR42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903\u2013912","journal-title":"Arch Ophthalmol"},{"key":"1908_CR43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/1523-1747.ep12313437","volume":"105","author":"A Osada","year":"1995","unstructured":"Osada A, Nakashima H, Furue M, Tamaki K (1995) Up-regulation of CD44 expression by tumor necrosis factor-alpha is neutralized by interleukin-10 in Langerhans cells. J Invest Dermatol 105:124\u2013127","journal-title":"J Invest Dermatol"},{"key":"1908_CR44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4049\/jimmunol.159.2.919","volume":"159","author":"SP Hart","year":"1997","unstructured":"Hart SP, Dougherty GJ, Haslett C, Dransfield I (1997) CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J Immunol 159:919\u2013925","journal-title":"J Immunol"},{"key":"1908_CR45","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H","volume":"41","author":"M Herrmann","year":"1998","unstructured":"Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241\u20131250","journal-title":"Arthritis Rheum"},{"key":"1908_CR46","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/ard.60.10.950","volume":"60","author":"AP Cairns","year":"2001","unstructured":"Cairns AP, Crockard AD, McConnell JR, Courtney PA, Bell AL (2001) Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 60:950\u2013955","journal-title":"Ann Rheum Dis"},{"key":"1908_CR47","doi-asserted-by":"crossref","unstructured":"Finckh A, Dudler J, Wermelinger F, Ciurea A, Kyburz D, Gabay C, Bas S, SCQM PO (2010) Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 77: 313\u2013318","DOI":"10.1016\/j.jbspin.2010.02.021"},{"key":"1908_CR48","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ibd.21259","volume":"16","author":"A Yamada","year":"2010","unstructured":"Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y (2010) Monitoring functional serum antitumor necrosis factor antibody level in Crohn\u2019s disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 16:1898\u20131904","journal-title":"Inflamm Bowel Dis"},{"key":"1908_CR49","doi-asserted-by":"crossref","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, investigators Es (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366: 1367\u20131374","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"1908_CR50","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","volume":"37","author":"E Adi\u015fen","year":"2010","unstructured":"Adi\u015fen E, Aral A, Aybay C, G\u00fcrer MA (2010) Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol 37:708\u2013713","journal-title":"J Dermatol"},{"key":"1908_CR51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjo.2009.174888","volume":"95","author":"S Sugita","year":"2010","unstructured":"Sugita S, Yamada Y, Mochizuki M (2010) Relationship between serum infliximab levels and acute uveitis attacks in patients with Beh\u00e7et disease. Br J Ophthalmol 95:549\u2013552","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-011-1908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-011-1908-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-011-1908-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T11:24:30Z","timestamp":1686655470000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-011-1908-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,11]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1007\/s00417-011-1908-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,11]]}}}